Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin PK/PD in Healthy Chinese Subjects
NCT03909451Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sotagliflozin in diabetes mellitus (DM) (3 arms), sponsored by Sanofi. Primary endpoint: Adverse Events up to 41 days. Started Apr 2019; status: completed.
02
Drugs
sotagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03909451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909451.